(Q36564975)

15 August 2017

1 reference

title

Targeting the epidermal growth factor receptor in the treatment of colorectal cancer: state of the art. (English)

1 reference

15 August 2017

1 reference

1 reference

Robert B Diasio

1

1 reference

15 August 2017

Jeanne Fourie

series ordinal

2

1 reference

15 August 2017

publication date

1 January 2006

1 reference

15 August 2017

1 reference

15 August 2017

volume

66

1 reference

15 August 2017

issue

11

1 reference

15 August 2017

page(s)

1441-1463

1 reference

Uncommon presentations of Hodgkin's disease. Case 3. Hodgkin's disease: rectal presentation

15 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200666110-00003

Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase

21 January 2018

1 reference

12 December 2020

Deletion-mutant epidermal growth factor receptor in human gliomas: Effect of type II mutation on receptor function

1 reference

12 December 2020

Rates of colon and rectal cancers are increasing in young adults

1 reference

12 December 2020

Vascular endothelial growth factor family members are differentially regulated by c-erbB signaling in head and neck squamous carcinoma cells.

1 reference

12 December 2020

Cyclooxygenases: structural, cellular, and molecular biology

1 reference

12 December 2020

Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.

1 reference

12 December 2020

Evaluation of malignancy and the prognosis of esophageal cancer based on an immunohistochemical study (p53, E-cadherin, epidermal growth factor receptor).

1 reference

12 December 2020

Human antibody effector function

1 reference

12 December 2020

Clinical experience with CD64-directed immunotherapy. An overview

1 reference

12 December 2020

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

1 reference

12 December 2020

Altered eicosanoid levels in human colon cancer

1 reference

12 December 2020

Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck

1 reference

12 December 2020

Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase

1 reference

12 December 2020

Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy

1 reference

12 December 2020

The schedule-dependent enhanced cytotoxic activity of 7-ethyl-10-hydroxy-camptothecin (SN-38) in combination with Gefitinib (Iressa, ZD1839).

1 reference

12 December 2020

Epidermal growth factor

1 reference

12 December 2020

Characterization of epidermal growth factor receptor gene expression in malignant and normal human cell lines

1 reference

12 December 2020

ErbB-targeted therapeutic approaches in human cancer

1 reference

12 December 2020

Epigenetic changes in colorectal cancer.

1 reference

12 December 2020

Monoclonal antibodies in human cancer

1 reference

12 December 2020

Treatment of advanced non-small-cell lung cancer with two-drug combinations

1 reference

12 December 2020

Improving the efficacy of antibody-based cancer therapies

1 reference

12 December 2020

The cellular response to neuregulins is governed by complex interactions of the erbB receptor family

1 reference

12 December 2020

Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results

1 reference

12 December 2020

Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth

1 reference

12 December 2020

Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor

1 reference

12 December 2020

Phase II trial of ZD1839 (IRESSA) in patients with advanced renal cell carcinoma

1 reference

12 December 2020

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

1 reference

12 December 2020

Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer

1 reference

12 December 2020

Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs.

1 reference

12 December 2020

Implication of a multisubunit Ets-related transcription factor in synaptic expression of the nicotinic acetylcholine receptor

1 reference

12 December 2020

Acute lung injury as an adverse event of gefitinib

1 reference

12 December 2020

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

12 December 2020

Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malig

1 reference

12 December 2020

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

1 reference

12 December 2020

Expression of cyclooxygenase-1 and -2 in human colorectal cancer

1 reference

12 December 2020

Epidermal growth factor receptor biology (IMC-C225).

1 reference

12 December 2020

Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy

1 reference

12 December 2020

Phase II study of capecitabine in patients with fluorouracil-resistant metastatic colorectal carcinoma

1 reference

12 December 2020

Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor.

1 reference

12 December 2020

Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression

1 reference

12 December 2020

Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.

1 reference

12 December 2020

Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts.

1 reference

12 December 2020

Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice

1 reference

12 December 2020

Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer

1 reference

12 December 2020

Expression of epidermal growth factor receptor mRNA and protein in primary breast carcinomas

1 reference

12 December 2020

Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck

1 reference

12 December 2020

ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells

1 reference

12 December 2020

Coxibs and cardiovascular disease

1 reference

12 December 2020

The ErbB signaling network: receptor heterodimerization in development and cancer

1 reference

12 December 2020

The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification

1 reference

12 December 2020

Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas

1 reference

12 December 2020

Clinical trial with escalating doses of the antiepidermal growth factor receptor humanized monoclonal antibody EMD 72 000 in patients with advanced squamous cell carcinoma of the larynx and hypopharynx

1 reference

12 December 2020

A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity

1 reference

12 December 2020

Epidermal growth factor receptor--mediated stat3 signaling blocks apoptosis in head and neck cancer

1 reference

12 December 2020

NCCN Clinical Practice Guidelines in Oncology: rectal cancer

1 reference

12 December 2020

Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme

1 reference

12 December 2020

The Hallmarks of Cancer

1 reference

12 December 2020

Production of macrophage-activated killer cells for targeting of glioblastoma cells with bispecific antibody to FcgammaRI and the epidermal growth factor receptor

1 reference

12 December 2020

Quantitative immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck

1 reference

12 December 2020

AEE788, a dual tyrosine kinase receptor inhibitor, induces endothelial cell apoptosis in human cutaneous squamous cell carcinoma xenografts in nude mice

1 reference

12 December 2020

EGF mutant receptor vIII as a molecular target in cancer therapy

1 reference

12 December 2020

Receptor dimerization is not a factor in the signalling activity of a transforming variant epidermal growth factor receptor (EGFRvIII).

1 reference

12 December 2020

Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer

1 reference

12 December 2020

Asynchronous modulation of transforming growth factor alpha and epidermal growth factor receptor protein expression in progression of premalignant lesions to head and neck squamous cell carcinoma.

1 reference

12 December 2020

Safety experience with IMC-C225, an anti-epidermal growth factor receptor antibody

1 reference

12 December 2020

Cetuximab targeted therapy: a new treatment paradigm for advanced colorectal cancer

1 reference

12 December 2020

EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF

1 reference

12 December 2020

The effect of gefitinib (Iressa, ZD1839) in combination with oxaliplatin is schedule-dependent in colon cancer cell lines

1 reference

12 December 2020

Evidence of high incidence of EGFRvIII expression and coexpression with EGFR in human invasive breast cancer by laser capture microdissection and immunohistochemical analysis

1 reference

12 December 2020

Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib

1 reference

12 December 2020

Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck

1 reference

12 December 2020

Erlotinib in lung cancer - molecular and clinical predictors of outcome

1 reference

12 December 2020

The Epstein-Barr virus latent membrane protein 1 induces expression of the epidermal growth factor receptor.

1 reference

12 December 2020

The roles of JNK1 and Stat3 in the response of head and neck cancer cell lines to combined treatment with all-trans-retinoic acid and 5-fluorouracil

1 reference

12 December 2020

The ErbB receptors and their role in cancer progression.

1 reference

12 December 2020

Expression of growth factors and their receptors in human esophageal carcinomas: regulation of expression by epidermal growth factor and transforming growth factor alpha

1 reference

12 December 2020

Phase II trial of gefitinib in recurrent glioblastoma

1 reference

12 December 2020

EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patients

1 reference

12 December 2020

Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer

1 reference

12 December 2020

Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation

1 reference

12 December 2020

Metastatic colorectal cancer

1 reference

12 December 2020

Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard.

1 reference

12 December 2020

Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene.

1 reference

12 December 2020

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

1 reference

12 December 2020

Pharmacological evaluation of humanized anti-epidermal growth factor receptor, monoclonal antibody h-R3, in patients with advanced epithelial-derived cancer

1 reference

12 December 2020

EGFR and cancer prognosis

1 reference

12 December 2020

Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial

1 reference

12 December 2020

Epidermal growth factor receptor dependence in human tumors: more than just expression?

1 reference

12 December 2020

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

1 reference

12 December 2020

Cyclooxygenase-2 overexpression inhibits platelet-derived growth factor-induced mesangial cell proliferation through induction of the tumor suppressor gene p53 and the cyclin-dependent kinase inhibitors p21waf-1/cip-1 and p27kip-1

1 reference

12 December 2020

Expression of epidermal growth factor receptor in human gastric and colonic carcinomas

1 reference

12 December 2020

Inhibition of epidermal growth factor receptor kinase induces protease-dependent apoptosis in human colon cancer cells☆☆☆

1 reference

12 December 2020

Monoclonal antibodies as therapeutic agents for cancer

1 reference

12 December 2020

Differential modulation of proliferation, matrix metalloproteinase expression and invasion of human head and neck squamous carcinoma cells by c-erbB ligands

1 reference

12 December 2020

Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients.

1 reference

12 December 2020

Epidermal growth factor receptor as a therapeutic target in colorectal cancer

1 reference

12 December 2020

Epidermal growth factor receptor expression correlates with poor survival in gastric adenocarcinoma from Mexican patients: a multivariate analysis using a standardized immunohistochemical detection system

1 reference

12 December 2020

The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling

1 reference

12 December 2020

Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors

1 reference

12 December 2020

Color multiplex polymerase chain reaction for quantitative analysis of epidermal growth factor receptor genes in colorectal adenocarcinoma

1 reference

12 December 2020

Expression of epidermal growth factor receptor in primary colorectal adenocarcinoma predicts expression in recurrent disease

1 reference

12 December 2020

Epidermal growth factor receptor: mechanisms of activation and signalling.

1 reference

12 December 2020

Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model

1 reference

12 December 2020

The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy

1 reference

12 December 2020

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

1 reference

12 December 2020

Molecular determinants of cetuximab efficacy

1 reference

12 December 2020

Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells

1 reference

12 December 2020

Epidermal growth factor receptor (EGFR) expression in childhood brain tumors.

1 reference

12 December 2020

Cancer Pharmacogenomics: SNPs, Chips, and the Individual Patient

1 reference

12 December 2020

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

12 December 2020

Computer simulated evolution of a network of cell-signaling molecules

1 reference

12 December 2020

Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance

1 reference

12 December 2020

Development of the epidermal growth factor receptor inhibitor Tarceva (OSI-774).

1 reference

12 December 2020

Tumor invasion: role of growth factor-induced cell motility

1 reference

12 December 2020

Involvement of p27KIP1 in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody

1 reference

12 December 2020

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

12 December 2020

Role of cyclooxygenase-2 in colorectal cancer

1 reference

12 December 2020

Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor in advanced brain tumor patients: preliminary study

1 reference

12 December 2020

Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin

1 reference

12 December 2020

Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways

1 reference

12 December 2020

Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients.

1 reference

12 December 2020

Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody

1 reference

12 December 2020

Receptors for epidermal growth factor and other polypeptide mitogens

1 reference

12 December 2020

Untangling the ErbB signalling network

1 reference

12 December 2020

Signaling through the epidermal growth factor receptor during the development of malignancy

1 reference

12 December 2020

Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.

1 reference

12 December 2020

Prognostic role of angiogenesis in colorectal cancer

1 reference

12 December 2020

Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas

1 reference

12 December 2020

Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas

1 reference

12 December 2020

Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer.

1 reference

12 December 2020

Receptor tyrosine kinase signalling as a target for cancer intervention strategies

1 reference

12 December 2020

The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma

1 reference

12 December 2020

Modulation of tyrosine, serine, and threonine phosphorylation and intracellular processing of the epidermal growth factor receptor by antireceptor monoclonal antibody

1 reference

12 December 2020

EGFR overexpression and radiation response in glioblastoma multiforme

1 reference

12 December 2020

Phosphorylation of extracellular signal-regulated kinase 1 and 2, protein kinase B, and signal transducer and activator of transcription 3 are differently inhibited by an epidermal growth factor receptor inhibitor, EKB-569, in tumor cells and normal

1 reference

12 December 2020

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

12 December 2020

Cyclooxygenase-2 and gastrointestinal cancer

1 reference

12 December 2020

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

1 reference

12 December 2020

A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer

1 reference

12 December 2020

Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study

1 reference

12 December 2020

Phase I study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer

1 reference

12 December 2020

Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145.

1 reference

12 December 2020

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

1 reference

12 December 2020

Different epidermal growth factor growth responses and receptor levels in human colon carcinoma cell lines

1 reference

12 December 2020

Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas

1 reference

12 December 2020

Induction of apoptosis and activation of the caspase cascade by anti-EGF receptor monoclonal antibodies in DiFi human colon cancer cells do not involve the c-jun N-terminal kinase activity

1 reference

12 December 2020

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

1 reference

12 December 2020

Reversible G(1) arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires up-regulation of p27(KIP1) independent of MAPK activity

1 reference

12 December 2020

Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial

1 reference

12 December 2020

Erlotinib in previously treated non-small-cell lung cancer

1 reference

12 December 2020

Nuclear targeting of Bax during apoptosis in human colorectal cancer cells

1 reference

12 December 2020

ZD1839 ('Iressa') as an anticancer agent

1 reference

12 December 2020

Characterization of sequence-dependent synergy between ZD1839 ("Iressa") and oxaliplatin.

1 reference

12 December 2020

Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor

1 reference

12 December 2020

Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck

1 reference

12 December 2020

Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase

1 reference

12 December 2020

Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms

1 reference

12 December 2020

Overexpression of EGFR and c-erbB2 causes enhanced cell migration in human breast cancer cells and NIH3T3 fibroblasts

1 reference

12 December 2020

A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients

1 reference

12 December 2020

PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner

1 reference

12 December 2020

XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer

1 reference

12 December 2020

1 reference

12 December 2020

Coexpression, prognostic significance and predictive value of EGFR, EGFRvIII and phosphorylated EGFR in colorectal cancer.

1 reference

12 December 2020

New Gaba-containing analogues of human growth hormone-releasing hormone (1-30)-amide: I. Synthesis and in vitro biological activity

1 reference

12 December 2020

Gefitinib (Iressa, ZD1839): a novel targeted approach for the treatment of solid tumors.

1 reference

12 December 2020

Synchronous coexpression of epidermal growth factor receptor and cyclooxygenase-2 in carcinomas of the uterine cervix: a potential predictor of poor survival

1 reference

12 December 2020

Retinoic acid normalizes the increased gene transcription rate of TGF-alpha and EGFR in head and neck cancer cell lines

1 reference

12 December 2020

Mouse-human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice

1 reference

12 December 2020

Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation.

1 reference

12 December 2020

Netrin-1 controls colorectal tumorigenesis by regulating apoptosis

1 reference

12 December 2020

The coxibs, selective inhibitors of cyclooxygenase-2.

1 reference

12 December 2020

Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition

1 reference

12 December 2020

Structural alterations of the epidermal growth factor receptor gene in human gliomas

1 reference

12 December 2020

The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities

1 reference

12 December 2020

Epidermal growth factor-related peptides and their receptors in human malignancies

1 reference

12 December 2020

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

1 reference

12 December 2020

Monoclonal antibodies as therapeutics in oncology

1 reference

12 December 2020

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention

1 reference

12 December 2020

Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors

1 reference

12 December 2020

ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.

1 reference

12 December 2020

Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

1 reference

12 December 2020

Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions

1 reference

12 December 2020

Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival

1 reference

12 December 2020

Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities

1 reference

12 December 2020

Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells

1 reference

12 December 2020

1 reference

12 December 2020

Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer

1 reference

12 December 2020

Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy

1 reference

12 December 2020

10.2165/00003495-200666110-00003

Identifiers

DOI

1 reference

Dimensions Publication ID

15 August 2017

1029223546

0 references

1 reference